Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Randomized Phase II Selection Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
- Status
- RECRUITING
- Phase
- PHASE2
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1